Trombosis
Haemostatic drug
Hemostatic drug
Haemostatic agent
Haemostatic
Hemostatic agent
Hemostatic
Hemostatic agents

[ Cerrar ]

thrombotarget

 

 thrombotargets

   
Thrombotargets has developed and adapted to High Throughput Screening, a new family of biological assays capable to quantify simultaneously clot formation and clot lysis (HemostaScreen), total antioxidant capacity (OxidantScreen) and low-density lipoprotein modification (AtheroScreen). With these proven proprietary new HTS Platforms (), Thrombotargets is creating a continuously novel and promising pipeline of drug candidates.
       

  
 

Hemophiliacs patient


New discover to treat all kinds of bleeding in hemophiliacs' patients and healthy subjects with congenital platelet disorders and hemorrhages. Know more about TT-103MH by Thrombotargets. 



Haemostatic drug

Know the novel TT-103MH, the haemostatic drug by Thrombotargets. It is a new way for treating topically all kinds of bleeding. See here the characteristics of this revolutionary haemostatic drug.

Antihemorrhagic drug

Know the TT-103MH by Thrombotargets. The antihemorrhagic drug that Thrombotargets' team is developing for bleeding treatments. Revolutionary topical administration. Know the characteristic of this antihemorrhagic drug.

Procoagulant disorders

TT-103MH is the unique procoagulant drug under development able to stop bleeding caused by heparin treatment. Contact us and know more about how you can find solution for procoagulant disorders with TT-103MH.

Thrombotargets is developing TT- 103MH, a novel and significantly radical approach for the treatment of bleeding disorders. Using a topical formulation TT-103MH, will be effective in treating:


TT-103MH
Therapeutics
Antihemorrhagic
BioPlatformScreen
Other services
© 2006 - Thrombotargets Corp. All rights reserved - coagulation - treatment